HIGHLIGHTS
SUMMARY
Both NCCN and European guidelines agree 5 of 19 on a minimally invasive surgical approach, even in patients with high-risk endometrial carcinoma. In this regard, both the NCCN and European guidelines suggest hormonal therapy (in patients with low grade, asymptomatic, and hormone_receptor-positive metastases), reserving chemotherapy for progression. The assessment of estrogen and progesterone receptor status in the primary tumor may not reflect the status in the recurrent or metastatic tumor, and thus a biopsy of recurrent or metastatic carcinomas for hormone_receptor analysis may be helpful. Surgical resection if feasible (+/- CHT + RT) or . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.